Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 146.09B |
| Revenue (ttm) | 12.52B |
| Net Income (ttm) | 1.24B |
| Shares Out | 1.71B |
| EPS (ttm) | 0.74 |
| PE Ratio | 115.31 |
| Forward PE | 60.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,618,404 |
| Average Volume | 18,788,626 |
| Open | 86.00 |
| Previous Close | 85.25 |
| Day's Range | 84.75 - 89.00 |
| 52-Week Range | 28.65 - 109.10 |
| Beta | 0.46 |
| RSI | 47.40 |
| Earnings Date | Nov 27, 2025 |
About Innovent Biologics
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec... [Read more]
Financial Performance
In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.
Financial numbers in CNY Financial StatementsNews
Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. The clinical Phase 1 data of IBI301...
Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
SAN FRANCISCO and SUZHOU, China , Nov. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
Innovent's License Deal Fails To Excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $ 11.4 billion, pocketing a big downpayment, so why did its stock price fall? Key Takeaways: Innovent and it...
China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study
China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the active ingredient in N...
Innovent Biologics' Mazdutide Surpasses Semaglutide In HbA1c And Weight Loss In Phase 3 Trial
(RTTNews) - Innovent Biologics Inc. (IVBXF, 01801.HK) announced positive results from its fourth Phase 3 clinical trial, DREAMS-3, evaluating mazdutide—a dual GLP-1 and glucagon receptor agonist. The ...
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group DREAMS-3 is the world's firs...
Market Today: Innovent and Takeda's $11.4B Deal Boosts Biotech Sector
Market Today: Innovent and Takeda's $11.4B Deal Boosts Biotech Sector
Innovent Biologics (IVBIY) and Takeda Partner for $11.4 Billion Cancer Therapy Deal
Innovent Biologics (IVBIY) and Takeda Partner for $11.4 Billion Cancer Therapy Deal
Innovent inks $11.4 billion cancer drug partnership with Japan's Takeda
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China.
Takeda And Innovent Biologics Sign Global Oncology Collaboration Outside Greater China
(RTTNews) - Takeda (TAK) has signed a license and collaboration agreement with Innovent Biologics to advance the development, manufacturing, and commercialization of two late-stage oncology therapies—...
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
China's Innovent Biologics said on Wednesday it had signed an $11.4 billion deal with Japan's Takeda Pharmaceutical Co to accelerate the development of its immuno-oncology and antibody-drug conjugate ...
Innovent's weight-loss drug highlights China challenge for Novo, Lilly
Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining tra...
Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali...
Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
SAN FRANCISCO and SUZHOU, China , Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercia...
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
SAN FRANCISCO and SUZHOU, China , Sept. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial...
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent B...
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were ...
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress | IVBIY Stock News
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress
SAN FRANCISCO and SUZHOU, China , Sept. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial...
Innovent Biologics estimates ~50% jump in 2025 revenue
Innovent Biologics reports interim results
Innovent Announces 2025 Interim Results and Business Updates
Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China , Aug. 27, 2...
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study ...
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2?-bias) in Squamous Non-Small Cell Lung Cancer | IVBIY Stock News
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China , Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and ...
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
SAN FRANCISCO and SUZHOU, China , Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...